Brett J. Hos

Brett J. Hos

Auto-generated profile, based on publicly available information

Brett J. Hos

Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2019 in OncoImmunology
Verified
Journal Article
Open access
BHBrett J. Hos
Brett J. Hos
MCMarcel G.M. Camps
Marcel G.M. Camps
JBJitske van Den Bulk
Jitske van Den Bulk
ETElena Tondini
Elena Tondini
TEThomas C. van Den Ende
Thomas C. van Den Ende
FOFerry Ossendorp
Ferry Ossendorp
The murine MC-38 colorectal cancer model is a commonly used model for cancer with high mutational burden, which is sensitive for immune checkpoint immunotherapy. We set out to analyze endogenous CD8+ T cell responses to MC-38 neo-antigens in tumor-bearing mice and after anti-PD-L1 checkpoint therapy. Through combination of whole-exome sequencing analysis with mass spectrometry of MHC class I eluted peptides we could identify eight candidate epitopes. Of these, a neo-epitope encoded by a point-mutation in the sequence of the ribosomal protein L18 (Rpl18) strongly dominated the CD8+ T cell response to our MC-38 cell-line in comparison to a previously described neo-epitope in the Adpgk protein. Therapeutic vaccination with synthetic peptides induced CD8+ T cell responses against the mutated Rpl18 epitope, which controlled tumor growth in vivo. This immunologically dominant response to mutated Rpl18 is of great importance in the development and optimization of immunotherapeutic strategies with the MC-38 tumor model.

26 April 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
BHBrett J. Hos
Brett J. Hos
ETElena Tondini
Elena Tondini
SKSander I. van Kasteren
Sander I. van Kasteren
FOFerry Ossendorp
Ferry Ossendorp
Progress made in peptide-based vaccinations to induce T-cell-dependent immune responses against cancer has invigorated the search for optimal vaccine modalities. Design of new vaccine strategies intrinsically depends on the knowledge of antigen handling and optimal epitope presentation in both major histocompatibility complex class I and -II molecules by professional antigen-presenting cells to induce robust CD8 and CD4 T-cell responses. Although there is a steady increase in the understanding of the underlying mechanisms that bridges innate and adaptive immunology, many questions remain to be answered. Moreover, we are in the early stage of exploiting this knowledge to clinical advantage. Several adaptations of peptide-based vaccines like peptide-adjuvant conjugates have been explored and showed beneficial outcomes in preclinical models; but in the clinical trials conducted so far, mixed results were obtained. A major limiting factor to unravel antigen handling mechanistically is the lack of tools to efficiently track peptide vaccines at the molecular and (sub)cellular level. In this mini-review, we will discuss options to develop molecular tools for improving, as well as studying, peptide-based vaccines.

11 October 2022 in Cell Reports
Verified
Journal Article
Open access
BHBrett J. Hos
Brett J. Hos
ETElena Tondini
Elena Tondini
MCMarcel G.M. Camps
Marcel G.M. Camps
WRWesley Rademaker
Wesley Rademaker
JBJitske van Den Bulk
Jitske van Den Bulk
FOFerry Ossendorp
Ferry Ossendorp
We report an approach to identify tumor-specific CD4+ T cell neo-epitopes of both mouse and human cancer cells by analysis of major histocompatibility complex (MHC) class II-eluted natural peptides. MHC class II-presented peptide sequences are identified by introducing the MHC class II transactivator (CIITA) in tumor cells that were originally MHC class II negative. CIITA expression facilitates cell-surface expression of MHC class II molecules and the appropriate peptide-loading machinery. Peptide elution of purified MHC class II molecules and subsequent mass spectrometry reveals oncoviral- and neo-epitopes as well as shared epitopes. Immunological relevance of these epitopes is shown by natural presentation by dendritic cells and immunogenicity. Synthetic peptide vaccination induced functional CD4+ T cell responses, which helped tumor control in vivo. Thus, this CIITA transfection approach aids to identify relevant T helper epitopes presented by any MHC class II allele that would be otherwise very difficult to predict and reveals important targets for cancer immunotherapy.

10 October 2016 in ACS Chemical Biology
Verified
Journal Article
Closed access
JPJoanna B. Pawlak
Joanna B. Pawlak
BHBrett J. Hos
Brett J. Hos
MGMichel J. van de Graaff
Michel J. van de Graaff
OMOtty A. Megantari
Otty A. Megantari
NMNico Meeuwenoord
Nico Meeuwenoord
SKSander I. van Kasteren
Sander I. van Kasteren

11 July 2025 in Cancer Immunology Research
Verified
Journal Article
Open access
ZSZiye Song
Ziye Song
YLYoukyung Lim
Youkyung Lim
AKAnneloes van Krimpen
Anneloes van Krimpen
MGMitchell A.A. Geleijnse
Mitchell A.A. Geleijnse
MMManon Messchendorp
Manon Messchendorp
CSChristopher Schliehe
Christopher Schliehe
Cytotoxic T lymphocytes screen cells for signs of infection and transformation by recognizing peptides displayed on MHC class I molecules. Next to canonical ATG-initiated open reading frames (ORF), noncanonical translation can result in synthesis of nonconventional or “cryptic” polypeptides. These can originate from translation initiation at noncanonical start codons, a process previously associated with inflammation and oncogenic transformation. Cryptic translation products are efficiently presented on MHC class I molecules and therefore increasingly recognized as potential targets for cancer immunotherapy. In this study, we studied the impact of localization of a CTG-initiated ORF relative to a canonical ATG start codon on cryptic expression after innate immune stimulation. We generated immortalized C57BL/6J mouse–derived bone marrow progenitor cells (HoxB8) expressing tandem minigene constructs, which encoded a CTG-driven chicken ovalbumin–derived SIINFEKL (S8L) epitope (CTG-S8L; H-2Kb restriced) either up- or downstream of a canonical ATG-initiated UTY-derived peptide WI9. The treatment of HoxB8-derived macrophages with Toll-like receptor agonists enhanced position-independent CTG-S8L translation, without affecting ATG-driven expression. Downstream CTG-S8L translation was driven by leaky scanning or ribosome re-initiation rather than read-through translation. Mouse AE17 mesothelioma and B16F10 melanoma cells expressing cryptic S8L either up- or downstream of a canonical ORF were efficiently killed by H-2Kb/S8L-restriced OT-I T cells in vitro, even though their antigen expression levels were extremely low. Mice implanted with tumors expressing cryptic S8L showed delayed tumor progression in vivo. In summary, our study contributes to the characterization of noncanonical start codon–driven cryptic antigen translation and highlights its potential for cancer immunotherapy.

1 August 2025
Verified
Other
Open access
ZSZiye Song
Ziye Song
YLYoukyung Lim
Youkyung Lim
AKAnneloes van Krimpen
Anneloes van Krimpen
MGMitchell A.A. Geleijnse
Mitchell A.A. Geleijnse
MMManon Messchendorp
Manon Messchendorp
CSChristopher Schliehe
Christopher Schliehe
Cytotoxic T lymphocytes screen cells for signs of infection and transformation by recognizing peptides displayed on MHC class I molecules. Next to canonical ATG-initiated open reading frames (ORF), noncanonical translation can result in synthesis of nonconventional or “cryptic” polypeptides. These can originate from translation initiation at noncanonical start codons, a process previously associated with inflammation and oncogenic transformation. Cryptic translation products are efficiently presented on MHC class I molecules and therefore increasingly recognized as potential targets for cancer immunotherapy. In this study, we studied the impact of localization of a CTG-initiated ORF relative to a canonical ATG start codon on cryptic expression after innate immune stimulation. We generated immortalized C57BL/6J mouse–derived bone marrow progenitor cells (HoxB8) expressing tandem minigene constructs, which encoded a CTG-driven chicken ovalbumin–derived SIINFEKL (S8L) epitope (CTG-S8L; H-2Kb restriced) either up- or downstream of a canonical ATG-initiated UTY-derived peptide WI9. The treatment of HoxB8-derived macrophages with Toll-like receptor agonists enhanced position-independent CTG-S8L translation, without affecting ATG-driven expression. Downstream CTG-S8L translation was driven by leaky scanning or ribosome re-initiation rather than read-through translation. Mouse AE17 mesothelioma and B16F10 melanoma cells expressing cryptic S8L either up- or downstream of a canonical ORF were efficiently killed by H-2Kb/S8L-restriced OT-I T cells in vitro, even though their antigen expression levels were extremely low. Mice implanted with tumors expressing cryptic S8L showed delayed tumor progression in vivo. In summary, our study contributes to the characterization of noncanonical start codon–driven cryptic antigen translation and highlights its potential for cancer immunotherapy.